Enterocolitis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2016, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Enterocolitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Enterocolitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Enterocolitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Enterocolitis.

Enterocolitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Enterocolitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Enterocolitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Enterocolitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Enterocolitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Enterocolitis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Enterocolitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Enterocolitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Enterocolitis Overview 6
Therapeutics Development 7
Pipeline Products for Enterocolitis - Overview 7
Pipeline Products for Enterocolitis - Comparative Analysis 8
Enterocolitis - Therapeutics under Development by Companies 9
Enterocolitis - Therapeutics under Investigation by Universities/Institutes 10
Enterocolitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Enterocolitis - Products under Development by Companies 13
Enterocolitis - Products under Investigation by Universities/Institutes 14
Enterocolitis - Companies Involved in Therapeutics Development 15
Angothera GmbH 15
AvidBiotics Corp. 16
Infant Bacterial Therapeutics AB 17
Sigma-Tau Pharmaceuticals, Inc 18
Enterocolitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
Antibodies for Enterocolitis - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
AvR2-V10 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
C-34 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
IBP-9414 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
melatonin - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
NRG-4 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules for Necrotizing Enterocolitis - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
STP-206 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Enterocolitis - Dormant Projects 38
Enterocolitis - Product Development Milestones 39
Featured News & Press Releases 39
Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial 39
Mar 31, 2016: IBT receives Rare Pediatric Disease Designation from FDA for drug candidate 39
Jan 08, 2016: BioGaia's subsidiary IBT has US IND open and Swedish CTA approved for clinical study 39
Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants 40
Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics 40
Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia 40
Feb 23, 2015: BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for Enterocolitis, H2 2016 7
Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Enterocolitis - Pipeline by Angothera GmbH, H2 2016 15
Enterocolitis - Pipeline by AvidBiotics Corp., H2 2016 16
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2016 17
Enterocolitis - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Enterocolitis - Dormant Projects, H2 2016 38